Combat

EIS eligible
EQUITY

Company overview

Combat has 2 hyperthermic drug delivery systems for the treatment of bladder cancer and cancers within the peritoneal cavity.

Maturity

Sales, or licensing phases

Sector

Drug Discovery

Market

Cancer therapeutics

Goal

£250,000.00

You can indicate your investment interest in this opportunity without any commitment.

What differentiates the company

HIGHLIGHTS

  • Technology platform that effectively delivers hyperthermia to various organs causing cancer cell death
  • 5 patents (2 granted in Europe, China, Japan & Australia)
  • 17,000 treatments completed & selling in 33 countries
  • Easy to use, affordable and high patient tolerability
I want to read the investment opportunity sheet

What our experts say  

THIS PROJECT HAS BEEN REVIEWED BY THE BIOEXPERT NETWORK OF 500+ PHD LEVEL SCIENTISTS, PHYSICIANS, IP LAWYERS, CONSULTANTS AND INVESTMENT PROFESSIONALS. THEY HAVE RATED THIS PROJECT BASED ON VARIOUS PARAMETERS, INCLUDING: THE SCIENTIFIC VALIDITY, TEAM EXPERTISE, ROUTE TO MARKET, VALUATION AND INVESTABILITY.

The final ratings  

THESE ARE THE AVERAGE SCORES, TAKEN FROM A VARIETY OF REVIEWS PERFORMED BY THE BIOEXPERT NETWORK AND OUR INTERNAL ANALYTICAL TEAM.

Team

WHAT'S THIS?
THE PROFESSIONAL EXPERTISE OF THE TEAM AND OVERALL STRUCTURE OF THE COMPANY.

Science

WHAT'S THIS?
THE CREDIBILITY OF THE SCIENTIFIC RESEARCH AND DEVELOPMENT, THE STATUS OF THE PATENT AND THE ACCURACY OF THE INFORMATION PRESENTED.

Innovation

WHAT'S THIS?
THE NOVEL MERIT OF THE PROJECT AND COMPARISON OF THE COMPANY TO COMPETITORS.

Business

WHAT'S THIS?
THE MATURITY OF THE COMPANY, AND APPROPRIACY OF THE BUSINESS MODEL, PLAN AND ROUTE TO MARKET.

Finance

WHAT'S THIS?
THE PRESENTATION OF FINANCIAL INFORMATION, INCLUDING PRE-MONEY VALUATION, BALANCE SHEET, FORECAST, EXPECTED ROI, EXIT AND ROI JUSTIFICATION.

Approved by the Bioexpert Network

The BioExpert Network is an independent and exclusive network of industry experts in the sectors of life science and investment. Only proposals which receive the most positive responses, in terms of novel concepts, scientific validity and financial accuracy successfully progress to funding campaign stage on the Capital Cell online platform.

Simple and beautiful: Hyperthermic Oncological Therapy

Cancer cells could be thought of as runaway, survivalist versions of normal cells; they reproduce out of control and keep living when they should die and be replaced. They are essentially mutants who ignore all normal cell behavior and cause mayhem by growing out of control. But let’s not forget that the body has trouble understanding this; to our body, a cell is a cell, regardless of how twisted and mutated it has become.

But that doesn’t mean that these cells aren’t different to normal cells. For example, they are very hungry – these cells consume more energy than ordinary ones. But there is a very particular thing about them that can be used to kill them: they just can’t take the heat.

“The combination of heat and chemotherapy is very effective against tumors”

  • Click to keep reading (2 min more)

    When a cell is too hot, it gets damaged beyond repair and does what all normal, well-behaved cells do: it turns itself in and volunteers to be destroyed. Heat-damaged cells plant on their outer membrane proteins called Heat Stress Signals, a sort of “flag” that signals the immune system to kill the cell and absorb it – this is our body’s normal recycling system.

    The really interesting point is this: healthy cells are generally OK up to 43,5 celsius, but most cancer cells can’t take anything above 41. Above this, things start happening: their outer walls become soft and permeable, making it all the easier for drugs to penetrate the cell. Not only that: they also start sending out heat stress signals. And as we know, sending those out means getting destroyed by the Immune system.

    All in all, it’s quite straightforward: the combination of heat and chemotherapy is very effective against tumors. So… forget all about complicated biotechnological treatments; washing a tumor in warm chemotherapy drugs is a great way to get rid of it.

    Based on this, Combat Medical have developed high precision, specialised equipment capable of circulating chemotherapy drugs at just the right temperature and with the right levels of agitation in bladder, colorectal and stomach cancers.

    Early clinical results in major UK and Spanish hospitals are showing >80% disease-free survival rates and over 17000 treatments have already been carried out, meaning this clinical method may already be a powerful new weapon in the arsenal against Cancer.

Daniel Oliver

Capital Cell CEO, Biologist and Crowdfunding Expert.
See my LinkedIn
daniel-project

Company Business Plan

Who we are

 

TEAM

Purpose of the project

 

FROM PROBLEM TO SOLUTION

THE PROBLEM

Other hyperthermia solutions have shown excellent clinical results, but failed commercially because they are too expensive, have patient tolerability issues (40% burns), are difficult to use and take up significant amounts of clinician’s time making them unscalable for mainstream use. Through Combat’s IP and know-how a technology platform has been created that has solved this and is easy to use. Its patented aluminum heat exchanger controls the temperature delivered within ±0.2°C, fluid flow rates and pressure delivered to the patient and the cancer (Duke Uni, USA). Hyperthermic drug delivery results in improved survival rates and significantly reduces recurrence rates and treatment cost.

THE SOLUTION

Combat has 2 hyperthermic drug delivery systems for the treatment of bladder cancer and cancers within the peritoneal cavity. These systems are simple, robust, CE marked, and the subject of 5 patent application families (some granted). Having placed over 17,000 kits on the market, Combat’s systems effectiveness has been validated. Its patented technologies enable the accurate control of temperature, flow and pressure. This allows for up to 10 times more drug to be absorbed, creates a natural immune response, and by delivering temperature within a tightly controlled range, it disrupts the cancer cells while leaving the good cells unaffected, leading to the death of the cancer cells.

Contact the Company

CONTACT THE COMPANY

Leave a Reply